STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease

Argenx said its blockbuster drug Vyvgart did not outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder. The late-stage study failure is described as an unusual setback for the company.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.